ERBB2 and breast cancer: Triple-negative breast cancers (TNBC) comprise 15% to 20% of all breast cancers and lack key clinical biomarkers [estrogen receptor (ER), progesterone receptor (PR), and HER2] that guide established molecularly targeted treatments for other breast cancer subtypes.